| Literature DB >> 35127088 |
Camille Van Bogaert1, Irina Vierasu1, Céline Mathey1, Aude Theunissen2, Serge Goldman1.
Abstract
This case report demonstrates the possible subclinical adrenal and pancreatic involvement in immunocompromised patients (in particular those with lymphoma) with a CMV infection and the role of whole-body 18F-FDG PET/CT in detecting these lesions.Entities:
Keywords: Non‐Hodgkin lymphoma; adrenal mass; cytomegalovirus; fluorodeoxyglucose positron emission tomography computed tomography (18F‐FDG PET/CT)
Year: 2022 PMID: 35127088 PMCID: PMC8795922 DOI: 10.1002/ccr3.5005
Source DB: PubMed Journal: Clin Case Rep ISSN: 2050-0904
FIGURE 1thoracoabdominal CT showing bilateral pulmonary opacities associated with a right lower lung mass (A) and multiple bi‐lobar liver lesions (B)
FIGURE 2(A) Fluorine‐18‐fluorodeoxyglucose positron emission tomography/computed tomography (18F‐FDG PET/CT) demonstrating hypermetabolic lesions in right pulmonary lower lobar mass with a necrotic center (cross) associated with hypermetabolic bi‐lobar liver lesions and supra and subdiaphragmatic lymph nodes. (B) 18F‐FDG PET/CT performed after 3 cycles of CHOP showing a partial response of pre‐existing lesions in the lower right lung, liver, and lymph nodes. New hypermetabolic lesions are evidenced at the level of bilateral pulmonary opacities, the spleen, and bilaterally in the adrenal glands (cross). (C) 18F‐FDG PET/CT realized after 6 cycles of chemotherapy and valganciclovir therapy demonstrating a complete response of liver and nodal lesions from lymphomatous origin. Splenic and adrenal lesions (cross) attributed to CMV infection have also disappeared under the dual therapy. The lung lesions of probable mixed origin – lymphoma and CMV – present with a partial response to this therapy. NB: red arrows =lymphoma, green arrows =CMV